Cellectis BioResearch Announces the Market Launch of a Revolutionary Research Kit
Product News Dec 02, 2008
The biotech company Cellectis BioResearch (a subsidiary of Cellectis S.A.) has announced the market launch of a research kit for producing stable cell clones using gene targeting in just 4 weeks. The first p10® class’ product is aimed at life science researchers worldwide and is available for immediate purchase.
Cellectis BioResearch will follow up this initial hamster cell kit by rolling out the product range to other species - notably including mouse and human cells.
"The p10.3® CHO kit is the result of 5 years of development work", stated Dr. André Choulika, Chairman of Cellectis BioResearch. "The use of meganucleases is revolutionizing targeted integration. Creating stable, targeted clones used to require between 6 and 12 months of cumbersome and unpredictable work. Our product performs this operation successfully in only 4 weeks".
"This first product is targeting a potential market of several million experiments a year”, added Marc Le Bozec, Managing Director of Cellectis BioResearch. “We are seeking to win a market share of a few percent within the mid-term and are developing a portfolio of 25 products in order to achieve that goal".